Effects of dopamine on kidney function and on the adenyl cyclase phosphodiesterase system in man.
Clearance studies were made to determine the influence of intravenous infusions of dopamine (between 2.5 and 3.5 mug.kg.-1min.-1) on renal function and on the adenyl cyclase phosphodiesterase system in eleven patients with chronic renal disease. Glomerular filtration rate (+ 19%), effective renal plasma flow )+ 29%), sodium (+ 199%) and potassium (+ 40%) clearances were significantly increased. These effects were associated with a stimulation of the adenyl cyclase phosphodiesterase system demonstrated by an increase of cyclic adenosine 3'5'-monophosphate in plasma and urine. The results suggest that dopamine probably affects renal function by activating the adenyl cyclase phosphodiesterase system.
D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000378:metabolism*; D000293:Adolescent; D000328:Adult; D000242:Cyclic AMP / Q000378:metabolism; D004298:Dopamine / Q000494:pharmacology*; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects; D005921:Glomerulonephritis / Q000201:enzymology; D006801:Humans; D007668:Kidney / Q000098:blood supply / Q000187:drug effects* / Q000201:enzymology; D008297:Male; D008875:Middle Aged; D009318:Natriuresis / Q000187:drug effects; D010727:Phosphoric Diester Hydrolases / Q000378:metabolism*; D011188:Potassium / Q000652:urine; D011704:Pyelonephritis / Q000201:enzymology; D012039:Regional Blood Flow / Q000187:drug effects
D000242:Cyclic AMP; D010727:Phosphoric Diester Hydrolases; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D011188:Potassium; D004298:Dopamine